This Article Full Text Full Text (PDF) Correction (v14,p4354) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Signoroni, S. Articles by Pilotti, S. Search for Related Content PubMed PubMed Citation Articles by Signoroni, S. Articles by Pilotti, S.

Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis

Authors' Affiliations: ¹ Experimental Molecular Pathology, Department of Pathology, ² Department of Experimental Oncology, ³ Preventive-Predictive Medicine Unit, and ⁴ Department of Medical Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori; and ⁵ IFOM, FIRC Institute of Molecular Oncology, Milan, Italy

Requests for reprints: Silvana Pilotti, Unit of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCSS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milan, Italy. Phone: 39-2-2390-2260; Fax: 39-2-2390-2877; E-mail: silvana.pilotti{at}istitutotumori.mi.it.

Purpose: To explore the molecular bases of potential new pharmacologic targets in aggressive fibromatosis (desmoid tumor).

Experimental Design: Tumor specimens from 14 patients surgically treated for aggressive fibromatosis (6 familial adenomatous polyposis and 8 sporadic cases), analyzed for adenomatous polyposis coli (APC) and CTNNB1 (ß-catenin) mutations, were further investigated for ß-catenin, cyclooxygenase-2 (COX-2), platelet-derived growth factor (PDGF) receptor (PDGFRA)/PDGF receptor ß (PDGFRB), their cognate ligands (PDGFA and PDGFB), and KIT using a comprehensive immunohistochemical, biochemical, molecular, and cytogenetic approach.

Results: No CTNNB1 (ß-catenin) mutations were found in the familial adenomatous polyposis patients, but previously reported activating mutations were found in six of the eight sporadic patients. All of the cases carrying an altered WNT pathway showed nuclear and cytoplasmic immunoreactivity for ß-catenin, whereas ß-catenin expression was restricted to the cytoplasm in the sporadic patients lacking CTNNB1 mutations. COX-2 protein and mRNA overexpression was detected in all 14 cases, together with the expression and phosphorylation of PDGFRA and PDGFRB, which in turn paralleled the presence of their cognate ligands. No PDGFRB mutations were found. The results are consistent with PDGFRA and PDGFRB activation sustained by an autocrine/paracrine loop.

Conclusions: Aggressive fibromatosis is characterized by WNT/oncogene pathway alterations triggering COX-2–mediated constitutive coactivation of PDGFRA and PDGFRB, and may therefore benefit from combined nonsteroidal anti-inflammatory drug + tyrosine kinase inhibitor treatment.

This article has been cited by other articles:

				I. Peerlinck, S. Amini-Nik, R. K. Phillips, R. Iggo, N. R. Lemoine, S. Tejpar, and G. Vassaux Therapeutic Potential of Replication-Selective Oncolytic Adenoviruses on Cells from Familial and Sporadic Desmoid Tumors Clin. Cancer Res., October 1, 2008; 14(19): 6187 - 6192. [Abstract] [Full Text] [PDF]